Quantum Biopharma Ltd. (QNTM)
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Quantum BioPharma Ltd.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 9, 2026 | 2.13 | 2.31 | 2.06 | 2.23 | 76,185 |
| Nov 6, 2026 | 2.05 | 2.17 | 2.04 | 2.10 | 43,625 |
| Nov 5, 2026 | 2.20 | 2.20 | 2.06 | 2.11 | 80,582 |
| Nov 4, 2026 | 2.21 | 2.25 | 2.17 | 2.21 | 45,578 |
| Nov 3, 2026 | 2.27 | 2.34 | 2.21 | 2.21 | 45,292 |
| Nov 2, 2026 | 2.41 | 2.44 | 2.20 | 2.26 | 57,377 |
| Oct 30, 2026 | 2.45 | 2.47 | 2.29 | 2.38 | 76,834 |
| Oct 29, 2026 | 2.43 | 2.50 | 2.35 | 2.44 | 52,674 |
| Oct 28, 2026 | 2.42 | 2.42 | 2.35 | 2.37 | 103,350 |
| Oct 27, 2026 | 2.21 | 2.40 | 2.17 | 2.32 | 86,828 |
| Oct 26, 2026 | 2.20 | 2.24 | 2.09 | 2.21 | 176,513 |
| Oct 23, 2026 | 2.26 | 2.37 | 2.24 | 2.24 | 42,708 |
| Oct 22, 2026 | 2.37 | 2.43 | 2.25 | 2.27 | 150,419 |
| Oct 21, 2026 | 2.45 | 2.48 | 2.37 | 2.40 | 90,607 |
| Oct 20, 2026 | 2.42 | 2.55 | 2.41 | 2.43 | 51,736 |
| Oct 19, 2026 | 2.49 | 2.55 | 2.40 | 2.41 | 63,599 |
| Oct 16, 2026 | 2.68 | 2.75 | 2.46 | 2.47 | 190,810 |
| Oct 15, 2026 | 2.65 | 2.74 | 2.60 | 2.71 | 107,517 |
| Oct 14, 2026 | 2.85 | 2.89 | 2.66 | 2.66 | 180,882 |
| Oct 13, 2026 | 2.83 | 2.97 | 2.80 | 2.89 | 84,863 |
| Name | Shares | % | Source |
|---|---|---|---|
AdvisorShares Investments LLC | 400.4K | 5.0% | 13F |
AdvisorShares Trust · also on 13F· may incl. warrants· filed Oct 2026 | 400.4K | 5.0% | 13G |
Malone Wealth Ventures LLC · may incl. warrants· filed Feb 2026 | 375.8K | 4.6% | 13G |
JANE STREET GROUP, LLC | 48.4K | 0.6% | 13F |
Platform Technology Partners | 41.1K | 0.5% | 13F |
UBS Group AG | 33.4K | 0.4% | 13F |
Steward Partners Investment Advisory, LLC | 27.9K | 0.3% | 13F |
CITADEL ADVISORS LLC | 15.9K | 0.2% | 13F |
Marex Group Ltd | 13.4K | 0.2% | 13F |
Mariner, LLC | 10.0K | 0.1% | 13F |
Quantum BioPharma Ltd., a biopharmaceutical firm headquartered in Toronto, Canada, is dedicated to the discovery and advancement of biotechnological solutions and drug candidates.
The company focuses on addressing complex neurodegenerative, inflammatory, and metabolic conditions, alongside alcohol use disorder, with its pipeline featuring a range of drug candidates at varying stages of development.
Its operations are divided into two main divisions: its core biopharmaceutical activities and strategic investment holdings. A flagship asset is Lucid-MS, a novel, proprietary chemical entity currently in Phase 2 clinical trials. Preclinical data indicates its potential to prevent and reverse the degradation of myelin, a key process underlying multiple sclerosis. Furthermore, Quantum BioPharma is developing a therapeutic solution for alcohol addiction, intended for application in hospital and clinical environments.
The company's strategic investments portfolio includes various loans collateralized by residential real estate. Previously known as FSD Pharma Inc., the company adopted its current name, Quantum BioPharma Ltd., in August 2024.
based on 8.09M shares outstanding
30d Avg
93.60K
60d Avg
151.81K
90d Avg
174.75K